Adlyfe, Inc. (Adlyfe) is a biotechnology company. It develops and markets biomarkers and diagnostic tests for neurodegenerative diseases. The company is developing a novel test for the detection and amplification of amyloid proteins as early biomarkers of fatal brain diseases. Its novel technology is based on the synthesis of small peptide ligands. It specifically focuses on developing novel tests for the detection of human neurodegenerative diseases, such as animal TSE diseases, and sporadic and variant Creutzfeldt-Jakob disease. The company is headquartered in Maryland, the US.